vs
Apellis Pharmaceuticals, Inc.（APLS）与SUPERIOR GROUP OF COMPANIES, INC.（SGC）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是SUPERIOR GROUP OF COMPANIES, INC.的1.4倍（$199.9M vs $146.6M），SUPERIOR GROUP OF COMPANIES, INC.净利率更高（2.4% vs -29.5%，领先31.9%），SUPERIOR GROUP OF COMPANIES, INC.同比增速更快（0.8% vs -5.9%），SUPERIOR GROUP OF COMPANIES, INC.自由现金流更多（$17.9M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 2.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
舒必利尔集团（Superior Coach）曾是美国汽车工业的车身制造商，其前身加尔福德卡车公司成立于1909年。该企业最为人熟知的业务是打造灵车等专业车辆车身以及校车车身。受1970年代末两大业务板块的严重衰退影响，公司于1980年被母公司清算，1925年至1980年间，企业总部设于俄亥俄州利马市。
APLS vs SGC — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $146.6M |
| 净利润 | $-59.0M | $3.5M |
| 毛利率 | — | 36.9% |
| 营业利润率 | -25.6% | 2.8% |
| 净利率 | -29.5% | 2.4% |
| 营收同比 | -5.9% | 0.8% |
| 净利润同比 | -62.2% | 65.8% |
| 每股收益（稀释后） | $-0.40 | $0.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $146.6M | ||
| Q3 25 | $458.6M | $138.5M | ||
| Q2 25 | $178.5M | $144.0M | ||
| Q1 25 | $166.8M | $137.1M | ||
| Q4 24 | $212.5M | $145.4M | ||
| Q3 24 | $196.8M | $149.7M | ||
| Q2 24 | $199.7M | $131.7M | ||
| Q1 24 | $172.3M | $138.8M |
| Q4 25 | $-59.0M | $3.5M | ||
| Q3 25 | $215.7M | $2.7M | ||
| Q2 25 | $-42.2M | $1.6M | ||
| Q1 25 | $-92.2M | $-758.0K | ||
| Q4 24 | $-36.4M | $2.1M | ||
| Q3 24 | $-57.4M | $5.4M | ||
| Q2 24 | $-37.7M | $600.0K | ||
| Q1 24 | $-66.4M | $3.9M |
| Q4 25 | — | 36.9% | ||
| Q3 25 | — | 38.3% | ||
| Q2 25 | — | 38.4% | ||
| Q1 25 | — | 36.8% | ||
| Q4 24 | — | 37.1% | ||
| Q3 24 | — | 40.4% | ||
| Q2 24 | — | 38.5% | ||
| Q1 24 | — | 39.8% |
| Q4 25 | -25.6% | 2.8% | ||
| Q3 25 | 48.7% | 2.3% | ||
| Q2 25 | -18.6% | 1.3% | ||
| Q1 25 | -50.0% | -0.7% | ||
| Q4 24 | -12.3% | 1.7% | ||
| Q3 24 | -24.0% | 4.4% | ||
| Q2 24 | -14.7% | 0.5% | ||
| Q1 24 | -36.0% | 3.3% |
| Q4 25 | -29.5% | 2.4% | ||
| Q3 25 | 47.0% | 2.0% | ||
| Q2 25 | -23.6% | 1.1% | ||
| Q1 25 | -55.3% | -0.6% | ||
| Q4 24 | -17.1% | 1.4% | ||
| Q3 24 | -29.2% | 3.6% | ||
| Q2 24 | -18.9% | 0.5% | ||
| Q1 24 | -38.5% | 2.8% |
| Q4 25 | $-0.40 | $0.23 | ||
| Q3 25 | $1.67 | $0.18 | ||
| Q2 25 | $-0.33 | $0.10 | ||
| Q1 25 | $-0.74 | $-0.05 | ||
| Q4 24 | $-0.30 | $0.12 | ||
| Q3 24 | $-0.46 | $0.33 | ||
| Q2 24 | $-0.30 | $0.04 | ||
| Q1 24 | $-0.54 | $0.24 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $23.7M |
| 总债务越低越好 | — | $94.1M |
| 股东权益账面价值 | $370.1M | $192.8M |
| 总资产 | $1.1B | $421.8M |
| 负债/权益比越低杠杆越低 | — | 0.49× |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $23.7M | ||
| Q3 25 | $479.2M | $16.7M | ||
| Q2 25 | $370.0M | $21.0M | ||
| Q1 25 | $358.4M | $19.8M | ||
| Q4 24 | $411.3M | $18.8M | ||
| Q3 24 | $396.9M | $18.4M | ||
| Q2 24 | $360.1M | $13.4M | ||
| Q1 24 | $325.9M | $22.0M |
| Q4 25 | — | $94.1M | ||
| Q3 25 | — | $100.0M | ||
| Q2 25 | — | $99.3M | ||
| Q1 25 | — | $95.7M | ||
| Q4 24 | — | $86.0M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
| Q4 25 | $370.1M | $192.8M | ||
| Q3 25 | $401.2M | $193.8M | ||
| Q2 25 | $156.3M | $192.1M | ||
| Q1 25 | $164.2M | $194.4M | ||
| Q4 24 | $228.5M | $198.9M | ||
| Q3 24 | $237.1M | $199.5M | ||
| Q2 24 | $264.3M | $200.9M | ||
| Q1 24 | $266.7M | $200.8M |
| Q4 25 | $1.1B | $421.8M | ||
| Q3 25 | $1.1B | $415.3M | ||
| Q2 25 | $821.4M | $423.3M | ||
| Q1 25 | $807.3M | $411.0M | ||
| Q4 24 | $885.1M | $415.1M | ||
| Q3 24 | $901.9M | $407.4M | ||
| Q2 24 | $904.5M | $400.3M | ||
| Q1 24 | $831.9M | $408.5M |
| Q4 25 | — | 0.49× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | 0.49× | ||
| Q4 24 | — | 0.43× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $18.4M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $17.9M |
| 自由现金流率自由现金流/营收 | -7.1% | 12.2% |
| 资本支出强度资本支出/营收 | 0.1% | 0.4% |
| 现金转化率经营现金流/净利润 | — | 5.32× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $15.8M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $18.4M | ||
| Q3 25 | $108.5M | $-1.7M | ||
| Q2 25 | $4.4M | $4.9M | ||
| Q1 25 | $-53.4M | $-2.0M | ||
| Q4 24 | $19.4M | $8.9M | ||
| Q3 24 | $34.1M | $8.2M | ||
| Q2 24 | $-8.3M | $6.9M | ||
| Q1 24 | $-133.0M | $9.4M |
| Q4 25 | $-14.3M | $17.9M | ||
| Q3 25 | $108.3M | $-2.4M | ||
| Q2 25 | $4.4M | $3.3M | ||
| Q1 25 | $-53.4M | $-3.1M | ||
| Q4 24 | $19.3M | $7.4M | ||
| Q3 24 | — | $7.3M | ||
| Q2 24 | $-8.4M | $5.6M | ||
| Q1 24 | $-133.3M | $8.8M |
| Q4 25 | -7.1% | 12.2% | ||
| Q3 25 | 23.6% | -1.7% | ||
| Q2 25 | 2.5% | 2.3% | ||
| Q1 25 | -32.0% | -2.3% | ||
| Q4 24 | 9.1% | 5.1% | ||
| Q3 24 | — | 4.9% | ||
| Q2 24 | -4.2% | 4.2% | ||
| Q1 24 | -77.3% | 6.3% |
| Q4 25 | 0.1% | 0.4% | ||
| Q3 25 | 0.0% | 0.5% | ||
| Q2 25 | 0.0% | 1.1% | ||
| Q1 25 | 0.0% | 0.8% | ||
| Q4 24 | 0.0% | 1.0% | ||
| Q3 24 | 0.0% | 0.6% | ||
| Q2 24 | 0.0% | 1.0% | ||
| Q1 24 | 0.2% | 0.5% |
| Q4 25 | — | 5.32× | ||
| Q3 25 | 0.50× | -0.61× | ||
| Q2 25 | — | 3.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.28× | ||
| Q3 24 | — | 1.52× | ||
| Q2 24 | — | 11.42× | ||
| Q1 24 | — | 2.41× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
SGC
| Branded Products | $96.9M | 66% |
| Healthcare Apparel | $28.8M | 20% |
| Contact Centers | $21.7M | 15% |
